Oligometastatic Prostate Carcinoma Clinical Trial
— OLIGOSOfficial title:
OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate
The proposed study consists of a multicentre prospective observational study involving patients with oligometastatic prostatic neoplasia defined according to CHAARTED criteria. The aim of the study is the creation of a registry including patients with newly diagnosed OMPCa, belonging to the main urological centres in the Triveneto region, in order to evaluate the oncological outcomes and the impact on the quality of life of local treatment of the primary neoplasm (surgical or radiotherapy) in addition to systemic hormonal treatment (ADT as monotherapy or in combination with Docetaxel/androgen receptor signal inhibitors (ARTA)). The above criteria define 'high metastatic volume' disease with the following parameters - ≥ 4 bone metastases, including at least one outside the spine and pelvis - Presence of visceral metastases Consequently, patients included in the study should not have the above-mentioned characteristics.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | January 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of new-onset prostate neoplasia (any risk category according to EAU guidelines). - Histological confirmation of disease by prostate biopsies. Absence of neuroendocrine differentiation - Low volume of metastatic disease defined according to CHAARTED study criteria (< of 4 bone metastases, absence of visceral metastases) - Patients without previous treatment of primary malignancy (e.g. previous radical prostatectomy, previous RT) - Patients treated with systemic therapy (ADT as monotherapy or in combination) for less than 6 months prior to enrolment - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Patients eligible for local treatment of primary malignancy and concomitant systemic therapy - Signature of informed consent Exclusion Criteria: - Inability or unwillingness to give written informed consent - High volume metastatic disease defined according to CHARTEED criteria - ECOG performance status > 1 - Patients included in other clinical trials - Contraindications to hormone/systemic therapy administration - Previous treatment of primary tumour (RP, RT or other treatment of primary tumour) |
Country | Name | City | State |
---|---|---|---|
Italy | Casa di Cura Abano Terme | Abano Terme | Padova |
Italy | Ospedale di Bassano Del Grappa | Bassano Del Grappa | Vicenza |
Italy | Ospedale di Bressanone | Bressanone | Bolzano |
Italy | Ospedale di Dolo | Dolo | Venezia |
Italy | Ospedale dell'Angelo - Mestre | Mestre | |
Italy | Azienda Ospedale Università Padova | Padova | |
Italy | Istituto Oncologico Veneto IRCCS | Padova | |
Italy | Ospedale MAter Salutis - Legnago | Padova | |
Italy | Ospedali Riuniti Padova Sud | Padova | |
Italy | Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI) | Trieste | |
Italy | Presidio Ospedaliero Universitario Santa Maria della Misericorida (ASU FC) | Udine | |
Italy | Azienda Ospedaliera Universitaria Integrata - Verona | Verona |
Lead Sponsor | Collaborator |
---|---|
Istituto Oncologico Veneto IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (OS) | Impact of primary tumour treatment in addition to systemic therapy on overall survival (OS) in patients with new-onset oligometastatic prostate neoplasia. | from the start date of the chosen treatment to the date of the subject's death from any cause, up to 3 years | |
Secondary | Cancer-specific survival | CSS is defined as the time (quantified in months) from the start date of the chosen treatment and the subject's death caused by the malignancy. | from the start date of the chosen treatment to the subject's death caused by the malignancy, up to 3 years. | |
Secondary | CRPCa development | Serum testosterone levels < 50 ng/dL or 1.7 nmol/L in association with biochemical progression or radiological progression | From the date of randomization up to 3 years | |
Secondary | Radiological progression-free survival | Definition of radiological progression (r-PFS): time from treatment start date to radiological progression (appearance of two or more new lesions on bone scintigraphy or appearance of visceral lesions). | From the treatment start date to radiological progression, up to 3 years | |
Secondary | Quality of life assessment | Assessment of QoL using the EuroQol 5-dimensional 5-level questionnaire (EQ-5D-5L)19 | From admission to discharge, assessed up to 3 years | |
Secondary | Quality of life assessment | Assessment of QoL using the EPIC-26 Short Form questionnaire. | From admission to discharge, assessed up to 3 years | |
Secondary | Complications | Evaluation of complications related to radiotherapy treatment, according to CTCAE v5.0 and surgical treatment, evaluated according to the Clavien Dindo classification | From admission to discharge, assessed up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05496959 -
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
|
Phase 2 | |
Withdrawn |
NCT04585932 -
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
|
Phase 2 | |
Not yet recruiting |
NCT05707468 -
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
|
N/A | |
Recruiting |
NCT06389786 -
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT04190446 -
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment
|
Phase 2 | |
Recruiting |
NCT06205316 -
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
|
Phase 3 | |
Recruiting |
NCT05053152 -
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06369610 -
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
|
Phase 2 |